ea0065p183 | Metabolism and Obesity | SFEBES2019
Colosimo Santo
, Brodosi Lucia
, Marchignoli Francesca
, Barbanti Francesca A
, Marchesini Giulio
, Petroni Maria Letizia
Background and aims: There is evidence that new anti-diabetic drugs may limit liver disease progression, reduce liver fat and normalize serum aminotranferase levels in patients with NAFLD. We compared the effectiveness of new drug classes on liver fat in T2DM patients by means of surrogate markers.Materials and methods: In an observational retrospective study we analysed the 12-month time-courses of clinical and anthropometric data of T2DM cases treated ...